JP2011507536A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011507536A5 JP2011507536A5 JP2010540060A JP2010540060A JP2011507536A5 JP 2011507536 A5 JP2011507536 A5 JP 2011507536A5 JP 2010540060 A JP2010540060 A JP 2010540060A JP 2010540060 A JP2010540060 A JP 2010540060A JP 2011507536 A5 JP2011507536 A5 JP 2011507536A5
- Authority
- JP
- Japan
- Prior art keywords
- arenavirus
- antigen
- rna
- foreign nucleic
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000712891 Arenavirus Species 0.000 claims 24
- 239000002245 particle Substances 0.000 claims 15
- 102000003886 Glycoproteins Human genes 0.000 claims 10
- 108090000288 Glycoproteins Proteins 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 108700026244 Open Reading Frames Proteins 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 230000014509 gene expression Effects 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 230000003612 virological effect Effects 0.000 claims 5
- 230000002458 infectious effect Effects 0.000 claims 4
- 239000004055 small Interfering RNA Substances 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 2
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims 2
- 102000011931 Nucleoproteins Human genes 0.000 claims 2
- 108010061100 Nucleoproteins Proteins 0.000 claims 2
- 102000029797 Prion Human genes 0.000 claims 2
- 108091000054 Prion Proteins 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 108091070501 miRNA Proteins 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 244000045947 parasite Species 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 1
- 208000024556 Mendelian disease Diseases 0.000 claims 1
- 108060004795 Methyltransferase Proteins 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102000017143 RNA Polymerase I Human genes 0.000 claims 1
- 108010013845 RNA Polymerase I Proteins 0.000 claims 1
- 102000009572 RNA Polymerase II Human genes 0.000 claims 1
- 108010009460 RNA Polymerase II Proteins 0.000 claims 1
- 102000014450 RNA Polymerase III Human genes 0.000 claims 1
- 108010078067 RNA Polymerase III Proteins 0.000 claims 1
- 241000725643 Respiratory syncytial virus Species 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 108020000999 Viral RNA Proteins 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108010025221 plasma protein Z Proteins 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 201000006152 substance dependence Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 210000002845 virion Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07025099 | 2007-12-27 | ||
| EP07025099.8 | 2007-12-27 | ||
| PCT/EP2008/010994 WO2009083210A1 (en) | 2007-12-27 | 2008-12-22 | Replication-defective arenavirus vectors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014151617A Division JP2014239688A (ja) | 2007-12-27 | 2014-07-25 | 複製欠損アレナウイルスベクター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011507536A JP2011507536A (ja) | 2011-03-10 |
| JP2011507536A5 true JP2011507536A5 (cg-RX-API-DMAC10.html) | 2013-02-21 |
| JP5642556B2 JP5642556B2 (ja) | 2014-12-17 |
Family
ID=40428182
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010540060A Active JP5642556B2 (ja) | 2007-12-27 | 2008-12-22 | 複製欠損アレナウイルスベクター |
| JP2014151617A Pending JP2014239688A (ja) | 2007-12-27 | 2014-07-25 | 複製欠損アレナウイルスベクター |
| JP2016216877A Active JP6227094B2 (ja) | 2007-12-27 | 2016-11-07 | 複製欠損アレナウイルスベクター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014151617A Pending JP2014239688A (ja) | 2007-12-27 | 2014-07-25 | 複製欠損アレナウイルスベクター |
| JP2016216877A Active JP6227094B2 (ja) | 2007-12-27 | 2016-11-07 | 複製欠損アレナウイルスベクター |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US8592205B2 (cg-RX-API-DMAC10.html) |
| EP (3) | EP2238255B1 (cg-RX-API-DMAC10.html) |
| JP (3) | JP5642556B2 (cg-RX-API-DMAC10.html) |
| CN (3) | CN103993012B (cg-RX-API-DMAC10.html) |
| CA (1) | CA2744910C (cg-RX-API-DMAC10.html) |
| DK (2) | DK2238255T3 (cg-RX-API-DMAC10.html) |
| ES (2) | ES2937147T3 (cg-RX-API-DMAC10.html) |
| FI (1) | FI2604695T3 (cg-RX-API-DMAC10.html) |
| HR (1) | HRP20221475T3 (cg-RX-API-DMAC10.html) |
| HU (1) | HUE061060T2 (cg-RX-API-DMAC10.html) |
| LT (1) | LT2604695T (cg-RX-API-DMAC10.html) |
| PL (2) | PL2604695T3 (cg-RX-API-DMAC10.html) |
| PT (1) | PT2604695T (cg-RX-API-DMAC10.html) |
| SI (1) | SI2604695T1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2009083210A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103993012B (zh) | 2007-12-27 | 2023-01-10 | 苏黎士大学 | 复制缺陷型沙粒病毒载体 |
| US20120219576A1 (en) * | 2009-09-16 | 2012-08-30 | The Administrators Of The Tulane Educational Fund | Lassa virus-like particles and methods of production thereof |
| WO2011156273A1 (en) * | 2010-06-06 | 2011-12-15 | Mount Sinai School Of Medicine | Recombinant rna viruses and uses thereof |
| WO2012162428A1 (en) | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| KR102314421B1 (ko) * | 2011-07-11 | 2021-10-19 | 이노비오 파마수티컬즈, 인크. | 교차-보호성 아레나바이러스 백신 및 이의 사용 방법 |
| EP4421177A3 (en) | 2013-03-13 | 2024-12-18 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Prefusion rsv f proteins and their use |
| US9809801B2 (en) | 2013-03-15 | 2017-11-07 | Université De Genève | Anti-mycobacterial vaccines |
| RS61993B1 (sr) | 2013-12-03 | 2021-07-30 | Hookipa Biotech Gmbh | Cmv vakcine |
| US10174317B2 (en) | 2014-02-13 | 2019-01-08 | Synthetic Genomics, Inc. | Recombinant RNA particles and methods of use |
| DK3105317T3 (en) * | 2014-02-14 | 2019-01-14 | Cellectis | Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells |
| BR112017005744B1 (pt) | 2014-09-22 | 2023-11-28 | Regents Of The University Of Minnesota | "vírus pichinde geneticamente manipulado, método de fabricação e uso do mesmo, partícula viral infecciosa, composição, coleção de vetores, sistema de genética reversa e método de uso do mesmo" |
| ES2811093T3 (es) * | 2014-11-13 | 2021-03-10 | Univ Geneve | Arenavirus trisegmentados como vectores de vacunas |
| DE102015207036A1 (de) | 2015-04-17 | 2016-10-20 | Karl Sebastian Lang | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
| HK1246183A1 (zh) * | 2015-06-10 | 2018-09-07 | Hookipa Biotech Gmbh | Hpv疫苗 |
| WO2018045029A1 (en) * | 2016-09-02 | 2018-03-08 | The United States Of America, As Represented By The Secretary Of The Army | Pan south american arenavirus live attenuated vaccine |
| WO2017076988A1 (en) * | 2015-11-04 | 2017-05-11 | Hookipa Biotech Ag | Vaccines against hepatitis b virus |
| EP3373959B1 (en) | 2015-11-12 | 2022-06-29 | Hookipa Biotech GmbH | Arenavirus particles as cancer vaccines |
| US11260090B2 (en) * | 2016-03-08 | 2022-03-01 | University Of Vermont And State Agricultural College | Modified arenavirus |
| IL262963B2 (en) * | 2016-05-18 | 2025-01-01 | Hookipa Biotech Gmbh | Trisegmented PICHINDE viruses as vaccine vectors |
| CN110167586B (zh) | 2016-11-04 | 2024-01-30 | 霍欧奇帕生物科技有限公司 | 作为癌症疫苗的复制-缺陷型沙粒病毒颗粒和三-节段沙粒病毒颗粒 |
| WO2018109220A2 (en) | 2016-12-16 | 2018-06-21 | Institute For Research In Biomedicine | Novel recombinant prefusion rsv f proteins and uses thereof |
| CN110719788A (zh) | 2017-04-07 | 2020-01-21 | 霍欧奇帕生物科技有限公司 | 治疗实体瘤的沙粒病毒颗粒 |
| DE102018215551A1 (de) | 2018-09-12 | 2020-03-12 | Virolutions Biotech Gmbh | Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten |
| WO2020255023A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof |
| AU2020315598B2 (en) | 2019-07-16 | 2024-12-12 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| HRP20241379T1 (hr) | 2019-09-30 | 2024-12-20 | Gilead Sciences, Inc. | Cjepiva za hbv i postupci za liječenje hbv |
| EP4045672A4 (en) * | 2019-10-18 | 2023-11-22 | University of Virginia Patent Foundation | COMPOSITIONS AND METHODS FOR PRODUCING ENHANCED IMMUNE RESPONSES AND RAPID ANTIBODY PRODUCTION |
| CN114981443A (zh) * | 2019-11-07 | 2022-08-30 | 巴塞尔大学 | 作为载体的沙粒病毒 |
| CA3202466A1 (en) | 2021-01-14 | 2022-07-21 | Jiani LI | Hiv vaccines and methods of using |
| MX2023011054A (es) | 2021-03-23 | 2023-11-22 | Hookipa Biotech Gmbh | Arenavirus utilizados en tratamientos del cáncer de próstata. |
| EP4337320A1 (en) | 2021-05-13 | 2024-03-20 | Hookipa Biotech GmbH | Arenaviruses as vectors |
| US20250073324A1 (en) | 2021-11-08 | 2025-03-06 | Hookipa Biotech Gmbh | Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies |
| EP4475879A1 (en) | 2022-02-08 | 2024-12-18 | Hookipa Biotech GmbH | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
| CN117343911A (zh) * | 2022-06-28 | 2024-01-05 | 中国科学院上海药物研究所 | 一种缺陷型丝状病毒的制备方法及其应用 |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
| AU2024343172A1 (en) | 2023-09-15 | 2026-03-05 | Gilead Sciences, Inc. | Arenavirus formulations, methods and uses thereof |
| CN117264909B (zh) * | 2023-10-25 | 2024-11-26 | 深圳湾实验室 | 反式互补缺陷猴痘病毒及其应用 |
| WO2025191169A1 (en) | 2024-03-15 | 2025-09-18 | Hookipa Biotech Gmbh | Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| US7267823B2 (en) | 1998-06-29 | 2007-09-11 | United States Of America As Represented By The Secretary Of The Army | Ebola peptides and immunogenic compositions containing same |
| DE19856463B4 (de) * | 1998-11-26 | 2006-02-02 | Heinrich-Pette-Institut | Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren |
| JP2000279178A (ja) * | 1999-02-24 | 2000-10-10 | Japan Found Cancer Res | ウイルスベクター |
| AU2002331572A1 (en) | 2002-04-17 | 2003-11-03 | Astropower, Inc. | Maximum power sensor for photovoltaic system |
| US7135339B2 (en) * | 2003-11-20 | 2006-11-14 | University Of Iowa Research Foundation | Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV) |
| WO2005061534A2 (en) | 2003-12-23 | 2005-07-07 | Statens Serum Institut | Improved tuberculosis vaccines |
| BRPI0518933A2 (pt) | 2004-11-16 | 2008-12-16 | Crucell Holland B V E Aeras Gl | adenovÍrus recombinante defeituoso de replicaÇço, vetor de polinucleotÍdeo recombinante, vacina multivalente da tuberculose, e, uso do antÍgeno tb10.4 de mycobacterium |
| DE102005006388A1 (de) | 2005-02-11 | 2006-08-24 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Replikationsdefiziente RNA-Viren als Impfstoffe |
| US20070005929A1 (en) * | 2005-06-30 | 2007-01-04 | Post Daniel J | Method, system, and article of manufacture for sector mapping in a flash device |
| CN103993012B (zh) * | 2007-12-27 | 2023-01-10 | 苏黎士大学 | 复制缺陷型沙粒病毒载体 |
| WO2012093340A2 (en) | 2011-01-07 | 2012-07-12 | Bioscience Slovakia | Viral diagnostics |
| US9809801B2 (en) | 2013-03-15 | 2017-11-07 | Université De Genève | Anti-mycobacterial vaccines |
| RS61993B1 (sr) | 2013-12-03 | 2021-07-30 | Hookipa Biotech Gmbh | Cmv vakcine |
| ES2811093T3 (es) | 2014-11-13 | 2021-03-10 | Univ Geneve | Arenavirus trisegmentados como vectores de vacunas |
| HK1246183A1 (zh) | 2015-06-10 | 2018-09-07 | Hookipa Biotech Gmbh | Hpv疫苗 |
| WO2017076988A1 (en) | 2015-11-04 | 2017-05-11 | Hookipa Biotech Ag | Vaccines against hepatitis b virus |
| EP3373959B1 (en) | 2015-11-12 | 2022-06-29 | Hookipa Biotech GmbH | Arenavirus particles as cancer vaccines |
| IL262963B2 (en) | 2016-05-18 | 2025-01-01 | Hookipa Biotech Gmbh | Trisegmented PICHINDE viruses as vaccine vectors |
| CN110167586B (zh) | 2016-11-04 | 2024-01-30 | 霍欧奇帕生物科技有限公司 | 作为癌症疫苗的复制-缺陷型沙粒病毒颗粒和三-节段沙粒病毒颗粒 |
| CN110719788A (zh) | 2017-04-07 | 2020-01-21 | 霍欧奇帕生物科技有限公司 | 治疗实体瘤的沙粒病毒颗粒 |
| CN114981443A (zh) | 2019-11-07 | 2022-08-30 | 巴塞尔大学 | 作为载体的沙粒病毒 |
| IL298420A (en) | 2020-05-29 | 2023-01-01 | Hookipa Biotech Gmbh | Cancer treatment strategies using RNA virus vectors |
| MX2023011054A (es) | 2021-03-23 | 2023-11-22 | Hookipa Biotech Gmbh | Arenavirus utilizados en tratamientos del cáncer de próstata. |
-
2008
- 2008-12-22 CN CN201410126161.5A patent/CN103993012B/zh active Active
- 2008-12-22 DK DK08868316.4T patent/DK2238255T3/da active
- 2008-12-22 PL PL13152727.7T patent/PL2604695T3/pl unknown
- 2008-12-22 JP JP2010540060A patent/JP5642556B2/ja active Active
- 2008-12-22 CN CN200880123157.6A patent/CN101918565B/zh active Active
- 2008-12-22 PT PT131527277T patent/PT2604695T/pt unknown
- 2008-12-22 US US12/810,382 patent/US8592205B2/en active Active
- 2008-12-22 HU HUE13152727A patent/HUE061060T2/hu unknown
- 2008-12-22 EP EP08868316.4A patent/EP2238255B1/en active Active
- 2008-12-22 ES ES13152727T patent/ES2937147T3/es active Active
- 2008-12-22 LT LTEP13152727.7T patent/LT2604695T/lt unknown
- 2008-12-22 WO PCT/EP2008/010994 patent/WO2009083210A1/en not_active Ceased
- 2008-12-22 DK DK13152727.7T patent/DK2604695T3/da active
- 2008-12-22 ES ES08868316.4T patent/ES2438773T3/es active Active
- 2008-12-22 CN CN2012104612347A patent/CN103255169A/zh active Pending
- 2008-12-22 EP EP22207314.0A patent/EP4186978A1/en active Pending
- 2008-12-22 CA CA2744910A patent/CA2744910C/en active Active
- 2008-12-22 PL PL08868316T patent/PL2238255T3/pl unknown
- 2008-12-22 EP EP13152727.7A patent/EP2604695B1/en active Active
- 2008-12-22 FI FIEP13152727.7T patent/FI2604695T3/fi active
- 2008-12-22 SI SI200832203T patent/SI2604695T1/sl unknown
- 2008-12-22 HR HRP20221475TT patent/HRP20221475T3/hr unknown
-
2013
- 2013-10-23 US US14/061,025 patent/US9309289B2/en active Active
-
2014
- 2014-07-25 JP JP2014151617A patent/JP2014239688A/ja active Pending
-
2016
- 2016-03-14 US US15/069,773 patent/US9944952B2/en active Active
- 2016-11-07 JP JP2016216877A patent/JP6227094B2/ja active Active
-
2018
- 2018-03-21 US US15/928,003 patent/US10655145B2/en active Active
-
2020
- 2020-04-29 US US16/861,758 patent/US11401528B2/en active Active
-
2022
- 2022-06-22 US US17/846,817 patent/US12227755B2/en active Active
-
2025
- 2025-01-07 US US19/012,351 patent/US20250369015A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vrba et al. | Development and applications of viral vectored vaccines to combat zoonotic and emerging public health threats | |
| Chaitanya | Structure and organization of virus genomes | |
| Barber | Vesicular stomatitis virus as an oncolytic vector | |
| US20220395585A1 (en) | Rna-based logic circuits with rna binding proteins, aptamers and small molecules | |
| Lichty et al. | Vesicular stomatitis virus: re-inventing the bullet | |
| Ungerechts et al. | Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses | |
| Ebert et al. | Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer | |
| RU2551982C2 (ru) | Способ получения поксвирусов и композиции поксвирусов | |
| Billeter et al. | Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses | |
| FI2604695T3 (fi) | Replikaatiokyvyttömiä arenavirusvektoreita | |
| JP2017527557A5 (cg-RX-API-DMAC10.html) | ||
| CN109312366A (zh) | 用于肿瘤溶瘤治疗的vsv/ndv杂合病毒 | |
| JP2008520248A (ja) | タンデム転写ユニットを有する組換えインフルエンザベクター | |
| Brun | Vaccines and vaccination for veterinary viral diseases: a general overview | |
| ES2689150T3 (es) | Métodos para la prevención de agregación de componentes víricos | |
| Morimoto et al. | Characterization of P gene-deficient rabies virus: propagation, pathogenicity and antigenicity | |
| Rehman et al. | Emerging biomedical applications of the vesicular stomatitis virus glycoprotein | |
| AU2018392826B2 (en) | Lassa vaccine | |
| Finke et al. | Recombinant rhabdoviruses: vectors for vaccine development and gene therapy | |
| Jogi et al. | Revolutionizing Veterinary Health with Viral Vector-Based Vaccines | |
| Zhu et al. | Reverse genetics of rabies virus: new strategies to attenuate virus virulence for vaccine development | |
| Iida et al. | Concept and technology underlying Sendai virus (SeV) vector development | |
| Chiozzini et al. | Extracellular vesicles and their use as vehicles of immunogens | |
| Kim et al. | Generation of recombinant viral hemorrhagic septicemia virus (rVHSV) expressing two foreign proteins and effect of lengthened viral genome on viral growth and in vivo virulence | |
| RU2807751C1 (ru) | Способ получения рекомбинантного вируса везикулярного стоматита |